Sana Biotechnology Inc. (SANA) is poised for a pivotal year in 2024, with plans to release preliminary data from its four ongoing clinical trials spanning seven different indications.
The company is focused on creating engineered cells as medicines for patients based on its hypoimmune technology. Its pipeline of drug candidates is strategically divided into three key categories - Oncology, B-cell Mediated Autoimmune Disease, and Regenerative Medicine.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.